カテゴリ： GlobalData, イギリス, 企業調査

Adaptimmune Therapeutics Plc (ADAP)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Adaptimmune Therapeutics Plc (ADAP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C8141
◆発行会社（調査会社）：GlobalData
◆発行日：2018年10月
◆ページ数：62
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：イギリス
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Adaptimmune Therapeutics Plc (Adaptimmune), formerly Adaptimmune Therapeutics Limited, is a clinical stage biopharmaceutical company that develops innovative T-cell therapy products for the treatment of cancer. It harnesses the proprietary SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell platform that engineers the T-cells to identify and exterminate cancer, including solid tumors. The company’s pipeline products include NY-ESO TCR for synovial sarcoma and multiple myeloma; MAGE A4 TCR for multiple solid tumors; AFP TCR for hepatocellular cancer; and MAGE-A10 TCR for bladder, melanoma, and head and neck cancer. The company has presence in the US and the UK. Adaptimmune is headquartered in Abingdon, Oxfordshire, the UK.

Adaptimmune Therapeutics Plc (ADAP) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Adaptimmune Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Adaptimmune Therapeutics Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Adaptimmune Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Adaptimmune Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Adaptimmune Therapeutics Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Adaptimmune Therapeutics Plc, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Adaptimmune Raises USD104 Million in Series A Venture Financing 12
Private Equity 14
Adaptimmune Therapeutics Raises USD100 Million in ADS 14
Partnerships 15
Adaptimmune Therapeutics Enters into Co-development Agreement with Bellicum Pharma 15
Adaptimmune Therapeutics Enters into Clinical Trial Agreement with Merck for Keytruda 16
Adaptimmune Therapeutics Enters into Agreement with University of Texas MD Anderson Cancer Center 17
Licensing Agreements 18
Adaptimmune Therapeutics Enters into Licensing Agreement with Thermo Fisher Scientific 18
Adaptimmune Therapeutics Enters into Licensing Agreement with Universal Cells 19
GlaxoSmithKline Exercises Licensing Agreement with Adaptimmune 20
GlaxoSmithKline Enters into Licensing Agreement with Adaptimmune Therapeutics 22
Adaptimmune Enters Into Licensing Agreement With Life Technologies 23
Equity Offering 24
Adaptimmune Therapeutics Raises USD42 Million in Private Placement of American Depositary Shares 24
Adaptimmune Therapeutics Raises USD65.9 Million in Public Offering of American Depositary Shares 25
Adaptimmune Therapeutics to Raise up to USD75 Million in Public Offering of American Depositary Shares 26
Adaptimmune Therapeutics Raises USD191.2 Million in IPO of American Depositary Shares 27
Adaptimmune Therapeutics Plc – Key Competitors 29
Adaptimmune Therapeutics Plc – Key Employees 30
Adaptimmune Therapeutics Plc – Locations And Subsidiaries 31
Head Office 31
Other Locations & Subsidiaries 31
Recent Developments 32
Strategy And Business Planning 32
Nov 06, 2017: Adaptimmune marks Official Opening of U.K. Headquarters 32
Financial Announcements 33
Mar 15, 2018: Adaptimmune Reports Fourth Quarter / Full Year 2017 Financial Results and Business Update 33
Nov 02, 2017: Adaptimmune Reports Third Quarter 2017 Financial Results and Business Updates 36
Aug 03, 2017: Adaptimmune Reports Second Quarter 2017 Financial Results 37
May 10, 2017: Adaptimmune Reports First Quarter 2017 Financial Results 39
Mar 13, 2017: Adaptimmune Reports Fourth Quarter and Full Year 2016 Financial Results 40
Corporate Communications 42
Apr 12, 2018: Adaptimmune Announces Changes to Board of Directors 42
Mar 15, 2017: Adaptimmune Broadens Executive Team 43
Jan 09, 2017: Adaptimmune Announces New Senior Vice President of Global Bio-Process and Development 44
Product News 45
11/10/2017: Adaptimmune Presents Study Design for Ongoing MAGE-A4 Clinical Trial at Society for Immunotherapy of Cancer Annual Meeting 45
08/15/2018: Third Dosing Cohort to be initiated in MAGE-A4 SPEAR T-cell Basket Study After Favorable Review of Safety from One Billion Cell Dose Cohort 46
07/18/2018: Adaptimmune announces favorable review of safety from one billion cell dose cohort in MAGE-A10 SPEAR T-cell study and initiation of third dosing cohorts 47
06/04/2018: Adaptimmune Presents Detailed Safety Update from Ongoing MAGE-A10 Pilot Studies at ASCO 48
05/16/2018: Adaptimmune to Present Data from MAGE-A10 Study at ASCO Annual Meeting 49
01/08/2018: Adaptimmune Announces Positive Safety Data from Pilot Studies with MAGE-A10 SPEAR T-cells and First Patient to Receive 1 billion Target Cell Dose 50
Product Approvals 51
Jan 09, 2017: Adaptimmune Announces FDA Acceptance of IND Application for Affinity Enhanced T-Cell Therapy Targeting MAGE-A4 in Multiple Solid Tumors 51
Clinical Trials 52
Jun 04, 2018: Adaptimmune Announces First Patient to Receive One Billion Target Cell Dose after Positive Safety Data from Pilot Study with MAGE-A4 SPEAR T-cells 52
Apr 16, 2018: Adaptimmune Presents Pre-clinical Data on MAGE-A10 SPEAR T-cells at AACR Annual Meeting 53
Apr 16, 2018: Adaptimmune Presents Pre-clinical Data on MAGE-A4 SPEAR T-cells at AACR Annual Meeting 54
Apr 06, 2018: Adaptimmune to Present Preclinical Data of MAGE-A10 SPEAR T-cells at AACR Annual Meeting 56
Apr 06, 2018: Adaptimmune to Present Preclinical Data of MAGE-A4 at AACR Annual Meeting 57
Nov 03, 2017: Adaptimmune to Present Update On MAGE-A4 Multi-tumor Study at Society for Immunotherapy of Cancer (SITC) Annual Meeting 58
May 16, 2017: Adaptimmune Announces Initiation of Study to Evaluate SPEAR T-Cell Therapy Targeting MAGE-A4 in Multiple Solid Tumors 59
May 10, 2017: Adaptimmune Announces Initiation of Study to Evaluate SPEAR T-Cell Therapy Targeting AFP in Liver Cancer 60
Other Significant Developments 61
Jan 08, 2018: Adaptimmune Announces Two Manufacturing Achievements on Its way to Become the First Fully Integrated TCR T-cell Therapy Company 61
Appendix 62
Methodology 62
About GlobalData 62
Contact Us 62
Disclaimer 62

List of Tables
Adaptimmune Therapeutics Plc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Adaptimmune Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Adaptimmune Therapeutics Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Adaptimmune Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Adaptimmune Therapeutics Plc, Deals By Therapy Area, 2012 to YTD 2018 9
Adaptimmune Therapeutics Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Adaptimmune Raises USD104 Million in Series A Venture Financing 12
Adaptimmune Therapeutics Raises USD100 Million in ADS 14
Adaptimmune Therapeutics Enters into Co-development Agreement with Bellicum Pharma 15
Adaptimmune Therapeutics Enters into Clinical Trial Agreement with Merck for Keytruda 16
Adaptimmune Therapeutics Enters into Agreement with University of Texas MD Anderson Cancer Center 17
Adaptimmune Therapeutics Enters into Licensing Agreement with Thermo Fisher Scientific 18
Adaptimmune Therapeutics Enters into Licensing Agreement with Universal Cells 19
GlaxoSmithKline Exercises Licensing Agreement with Adaptimmune 20
GlaxoSmithKline Enters into Licensing Agreement with Adaptimmune Therapeutics 22
Adaptimmune Enters Into Licensing Agreement With Life Technologies 23
Adaptimmune Therapeutics Raises USD42 Million in Private Placement of American Depositary Shares 24
Adaptimmune Therapeutics Raises USD65.9 Million in Public Offering of American Depositary Shares 25
Adaptimmune Therapeutics to Raise up to USD75 Million in Public Offering of American Depositary Shares 26
Adaptimmune Therapeutics Raises USD191.2 Million in IPO of American Depositary Shares 27
Adaptimmune Therapeutics Plc, Key Competitors 29
Adaptimmune Therapeutics Plc, Key Employees 30
Adaptimmune Therapeutics Plc, Other Locations 31
Adaptimmune Therapeutics Plc, Subsidiaries 31

List of Figures
Adaptimmune Therapeutics Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Adaptimmune Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Adaptimmune Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Adaptimmune Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Adaptimmune Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Adaptimmune Therapeutics Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Adaptimmune Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Adaptimmune Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Adaptimmune Therapeutics Plc (ADAP)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Takeda Pharmaceutical Co Ltd (4502)：企業の財務・戦略的SWOT分析
    Takeda Pharmaceutical Co Ltd (4502) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • LifeVantage Corp (LFVN)：企業の財務・戦略的SWOT分析
    Summary LifeVantage Corp (LifeVantage) is a science-based nutraceutical company that manufactures and markets dietary supplements. The company provides products such as protandim, axio, physiq, truescience and canine health, among others. Its beauty products include cleansers, hand creams, micro lif …
  • Fuji Electric Co., Ltd.：企業の戦略・SWOT・財務情報
    Fuji Electric Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Fuji Electric Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Hal Trust
    Hal Trust - Strategy, SWOT and Corporate Finance Report Summary Hal Trust - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • NICO Life Insurance Co Ltd：企業の戦略的SWOT分析
    NICO Life Insurance Co Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • ALK-Abello AS.：企業の戦略・SWOT・財務情報
    ALK-Abello AS. - Strategy, SWOT and Corporate Finance Report Summary ALK-Abello AS. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • St.George Bank：企業の戦略的SWOT分析
    St.George Bank - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • Zaraplast S.A：企業の戦略・SWOT・財務情報
    Zaraplast S.A - Strategy, SWOT and Corporate Finance Report Summary Zaraplast S.A - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Tenaska Inc：電力：M&Aディール及び事業提携情報
    Summary Tenaska Inc (Tenaska) is an independent power development and energy marketing company. It develops, designs, finances, and manages and operates power plants. The company purchases and sells natural gas, electric capacity, energy, and renewable energy products; acquires, manages, and optimiz …
  • Cinkarna Celje d.d. Celje (CICG)：企業の財務・戦略的SWOT分析
    Cinkarna Celje d.d. Celje (CICG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Miele & Cie. KG：企業の戦略的SWOT分析
    Miele & Cie. KG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • NOW Health Group Inc：企業の戦略・SWOT・財務情報
    NOW Health Group Inc - Strategy, SWOT and Corporate Finance Report Summary NOW Health Group Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Asahi Kasei Corp (3407)：企業の財務・戦略的SWOT分析
    Asahi Kasei Corp (3407) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • TOA Corporation：企業の戦略・SWOT・財務情報
    TOA Corporation - Strategy, SWOT and Corporate Finance Report Summary TOA Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Green Dot Corporation
    Green Dot Corporation - Strategy, SWOT and Corporate Finance Report Summary Green Dot Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Hawkins Inc (HWKN)：企業の財務・戦略的SWOT分析
    Hawkins Inc (HWKN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • American States Water Company (AWR)：企業の財務・戦略的SWOT分析
    Summary American States Water Company (AWR) operates as a utility service provider that offers water, wastewater and electric services. The utility provides operation, construction management and maintenance services for water and wastewater systems located on military bases across the US. It offers …
  • Chiyoda Corp (6366)：企業の財務・戦略的SWOT分析
    Chiyoda Corp (6366) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Antibe Therapeutics Inc (ATE)-製薬・医療分野：企業M&A・提携分析
    Summary Antibe Therapeutics Inc (Antibe) is a biotechnology company that designs and develops drug candidates for chronic pain and inflammation; and regenerative medicine. The company discovers and commercialize novel drugs, biologics and medical devices. It offers lead compound ATB-346, a naproxen …
  • Lisi Aerospace SAS：戦略・SWOT・企業財務分析
    Lisi Aerospace SAS - Strategy, SWOT and Corporate Finance Report Summary Lisi Aerospace SAS - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆